Form 4: Incyte EVP of Human Resources Reports Significant Equity Awards and Tax-Related Share Dispositions

Paula J. Swain, Executive Vice President of Human Resources at Incyte Corp, reported the acquisition of new restricted stock units, performance shares, and stock options, alongside the disposition of shares for tax withholding purposes.

Summary

• Paula J. Swain, EVP, Human Resources at Incyte Corp (INCY), reported several equity transactions.
• On July 14, 2025, 444 shares of common stock were disposed of at $69.98 per share to satisfy tax withholding obligations.
• On July 15, 2025, an additional 563 shares of common stock were disposed of at $68.25 per share for tax withholding.
• On July 15, 2025, 6,430 restricted stock units (RSUs) were awarded at $0, which will vest 25% annually over four years and settle one-for-one for common stock.
• On July 15, 2025, 16,077 performance shares were awarded at $0, which can yield up to 200% of one common share based on Incyte's relative total shareholder return (TSR) over a three-year period starting January 1, 2025, vesting on July 15, 2028.
• On July 15, 2025, 14,472 employee stock options were awarded at an exercise price of $68.25, with 25% vesting after one year and the remainder vesting monthly over three years, expiring on July 14, 2035.
• Following these transactions, Paula J. Swain beneficially owns 106,482 shares of common stock directly, including an aggregate of 37,390 unvested shares from previously reported RSUs and earned performance stock units.
• Additionally, 16,077 performance shares and 14,472 employee stock options are beneficially owned directly.

Sentiment

Score: 5

Explanation: Neutral. This is a routine disclosure of executive compensation and share transactions for tax purposes, which does not inherently indicate positive or negative company performance or outlook.

Positives

• Award of 6,430 restricted stock units (RSUs) to a key executive, aligning management incentives with shareholder value.
• Grant of 16,077 performance shares, which can yield up to 200% of common stock based on strong relative total shareholder return (TSR) performance.
• Issuance of 14,472 employee stock options, providing long-term incentives for the executive.
• The new equity awards demonstrate continued commitment to executive compensation tied to company performance and retention.

Negatives

• Disposition of 444 shares at $69.98 and 563 shares at $68.25 for tax withholding purposes, representing a reduction in direct common stock holdings.

Risks

• The value of performance shares is contingent on Incyte's relative total shareholder return (TSR) performance against a peer group over a three-year period, meaning the full potential payout is not guaranteed.
• The vesting of restricted stock units, performance shares, and employee stock options is subject to the reporting person's continued service with the issuer, posing a risk of forfeiture if employment ceases.
• The value of stock options is dependent on the future market price of Incyte common stock exceeding the exercise price of $68.25.

Future Outlook

The document indicates future vesting schedules for equity awards, with restricted stock units vesting 25% annually over four years, performance shares vesting on July 15, 2028, based on a three-year TSR performance period starting January 1, 2025, and employee stock options vesting 25% after one year and monthly over the subsequent three years, expiring on July 14, 2035. These awards are designed to incentivize long-term performance and retention.

Industry Context

This Form 4 filing reflects a routine executive compensation event, common across the pharmaceutical and biotechnology industries, where equity awards like RSUs, performance shares, and stock options are standard tools for attracting, retaining, and incentivizing senior management. The use of performance shares tied to relative Total Shareholder Return (TSR) is a common practice to align executive compensation with shareholder value creation in competitive sectors like biotech.

Comparison to Industry Standards

• The structure of equity compensation, including restricted stock units, performance shares, and stock options, is consistent with common practices in the pharmaceutical and biotechnology industries for executive remuneration.
• The vesting schedule for RSUs (25% annually over four years) and stock options (25% after one year, then monthly over three years) is a standard approach to ensure long-term retention and incentivize sustained performance, comparable to practices at companies like Gilead Sciences, Amgen, or Bristol Myers Squibb.
• The use of performance shares tied to relative Total Shareholder Return (TSR) over a three-year period is a widely adopted metric for performance-based equity awards in the biotech sector, aligning executive incentives with shareholder returns relative to a peer group, similar to compensation structures seen at large-cap biotech firms.

Related Party Transactions

• The equity awards (restricted stock units, performance shares, and employee stock options) granted to Paula J. Swain, an Executive Vice President, constitute related party transactions as they involve compensation from the issuer to a key management personnel.

Stakeholder Impact

• Shareholders: The equity awards align the interests of a key executive with shareholders by tying a significant portion of compensation to company performance and share price appreciation. The disposition of shares for tax withholding is a common event and has minimal impact.
• Employees: The compensation structure for a senior executive may set a precedent or reflect the company's overall approach to incentivizing its workforce, potentially impacting employee morale and retention strategies.
• Management: The awards provide long-term incentives and retention for the EVP of Human Resources, crucial for stable leadership and strategic execution.

Next Steps

• Continued vesting of 6,430 restricted stock units over the next four years.
• Vesting of 16,077 performance shares on July 15, 2028, contingent on Incyte's relative TSR performance.
• Continued vesting of 14,472 employee stock options over the next four years.

Key Dates

Keywords

Incyte Corp, INCY, SEC Form 4, executive compensation, restricted stock units, RSUs, performance shares, stock options, equity awards, total shareholder return, TSR, tax withholding, beneficial ownership